A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis.
autoimmune hepatitis
check point inhibitor
chemotherapy
drug induced liver injury
drug-induced autoimmune hepatitis
hepatitis
ipilimumab
nivolumab
renal cell carcinoma
steroid refractory
tocilizumab
Journal
ACG case reports journal
ISSN: 2326-3253
Titre abrégé: ACG Case Rep J
Pays: United States
ID NLM: 101638398
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
18
04
2023
accepted:
29
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.
Identifiants
pubmed: 37753105
doi: 10.14309/crj.0000000000001162
pii: ACGCR-23-0342
pmc: PMC10519460
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01162Informations de copyright
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
World J Gastroenterol. 2021 Aug 28;27(32):5376-5391
pubmed: 34539139
Tumori. 2021 Aug;107(4):304-310
pubmed: 32935638
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Gastroenterology. 2021 Mar;160(4):1384-1393
pubmed: 33080231
Cancer Med. 2020 Oct;9(19):7052-7061
pubmed: 32780516
J Clin Oncol. 2012 Jun 10;30(17):2046-54
pubmed: 22547592
J Oncol Pharm Pract. 2019 Apr;25(3):551-557
pubmed: 29207939
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692